Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on MIDATECH PHARMA PLC. We currently have 57 research reports from 4 professional analysts.
|14Mar17 07:00||RNS||Notice of Results|
|10Mar17 07:00||RNS||Midatech Announces Initial Scale-Up of Facility|
|27Feb17 07:00||RNS||Midatech enters into Loan Agreement with SVB|
|20Jan17 11:05||RNS||Second Price Monitoring Extn|
|20Jan17 11:00||RNS||Price Monitoring Extension|
|20Jan17 07:00||RNS||Trading Update|
|20Dec16 12:56||RNS||Director/PDMR Shareholding|
Frequency of research reports
Research reports on
MIDATECH PHARMA PLC
MIDATECH PHARMA PLC
Panmure Morning Note 10-03-2017
10 Mar 17
Midatech has announced the successful initial scale-up and regulatory inspection of its state-of-the-art manufacturing site in Bilbao, Spain. Investors will be familiar with Midatech’s product candidate Q-Octreotide (acromegaly and carcinoid syndrome) which is currently in development. This will be the first sustained release product to be produced at the Bilbao facility and such a strategy clearly provides the company with the flexibility to manage manufacture of the product in line with development, launch and subsequent commercialisation. We maintain our Buy recommendation.
PG: Growth Prospects in Healthcare
26 Jan 17
We expect the volatility of the last 3 months to continue, with macro events, particularly the uncertainty brought by President Trump and his focus on pharma pricing and dismantling the Affordable Care Act, likely to keep healthcare in the headlines for the wrong reasons. We believe the more highly valued larger stocks are likely to struggle to break out to new trading levels, but note there remains good value within the smaller end of the sector for stockpickers, with company specific events likely to drive some stocks well ahead of the crowd.
N+1 Singer - Morning Song 20-01-2017
20 Jan 17
Abzena (ABZA LN) ThioBridge™ licensing deal demonstrates technology leadership | Halfords Group (HFD LN) Positive lead indicators + FX mitigation progress | Midatech Pharma (MTPH LN) FY trading update: revenue ahead of estimates | MySale Group (MYSL LN) Strong progress in H1; positive momentum bodes well for H2 | PCI-PAL (PCIP LN) H1 revenue slightly ahead, CFO stepping down | Raven Russia Ltd (RUS LN) A step forward | SDL (SDL LN) Transformation progressing well | Synthomer (SYNT LN) Positive trading update and forecast upgrade
N+1 Singer - Midatech Pharma - FY trading update: revenue ahead of estimates
20 Jan 17
Midatech’s FY trading update indicates revenue for the period of c. £9.0m, ahead of our £8.0m estimate. The £16.7m (gross) capital raise announced in October allows Midatech to accelerate development of its key programmes. We continue to expect data from a gold nanoparticle (GNP) enabled Phase I diabetes vaccine trial in 2017, followed by the start of clinical trials in brain and liver cancer by early 2018. In addition, Q-Octreotide in our view represents a significant near-term licensing opportunity. We reiterate our Buy recommendation.
Panmure Morning Note 20-01-2017
20 Jan 17
Midatech Pharma’s trading update for the 12 months to 31 December 2016 reports ‘good progress across the group’ with total reported revenues expected to be circa £9.0m (2015: £1.4m). On this basis, the revenue performance for the year comes in-line with our top-of-the-range forecast (and is circa +4.9% vs consensus) and provides excellent validation of the group’s commercial capabilities and the potential of its US commercial presence. We believe the news flow, particularly as we look towards updates on Q-Octreotide in the coming months, reflects management’s ambitions and capabilities in building an international specialty pharmaceutical business, and we consider the wider business well-set to continue on its planned growth profile. Buy.
Panmure Morning Note 22-11-2016
22 Nov 16
Midatech’s previously-announced programme (04 January 2016) in conjunction with Emergex (infectious disease) has today crystallised an upfront technology access fee and option payment of £450,000 to Midatech. We think today’s news represents a strong validating point within the relationship between the two companies and consider the programme sits in a highly complementary manner alongside Midatech’s programmes in immunotherapy, auto-immune disease and immuno-oncology. We remain Buyers and repeat our 297p target price.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
N+1 Singer - EKF Diagnostics - Final results & potential buy back
20 Mar 17
FY16 prelims are slightly ahead of our latest expectations, those having been increased materially over the course of H2’16 as the strength of the recovery in trading became apparent. In order to maximise shareholder value, the directors are currently examining a potential break up of the group. This would also involve a delisting from AIM. A buy back offer at 21.5p would therefore be made to those investors that wish to exit now rather than holding their shares for the two years plus it would likely take to achieve a potentially higher realisation value for the businesses.
Good results, but further restructuring complex for investors
20 Mar 17
EKF Diagnostics FY 2016 results are slightly ahead of expectations, with both higher revenue and better EBITDA. Management has also announced plans to split the company into two separate companies, Point of Care and Laboratory Diagnostics, with the prospect of a delisting to manage the process. The primary metric for valuation of the two businesses is different consequently we believe that the separation is likely to generate significant value. However, in anticipation of the volatility likely given the restructuring announced this morning, despite the strength of the results, we reduce our recommendation to HOLD and maintain our 21p target price.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
N+1 Singer - N1S Trend spotting - Strategy update
08 Mar 17
In this new product we present some strategy theme updates arising out of our latest analysis of macro trends and economic data and our innovative Quant work. We also look at upcoming events and suggest topping up on some of our Best Ideas for 2017.